

Agilent, Merck & Danaher invest in enzymatic DNA printer

05 August 2020 | News

DNA Script will soon begin testing the SYNTAX™ system with a select group of partners



Paris based DNA synthesis company DNA Script has announced a \$50 million extension to its Series B financing, bringing the total investment of this round to \$89 million.

This oversubscribed round is led by Casdin Capital and joined by Danaher Life Sciences, Agilent Technologies, Merck KGaA, Darmstadt, Germany, through its corporate venture arm, M Ventures — three of the world's leaders in oligo synthesis — LSP, the Bpifrance Large Venture Fund and Illumina Ventures. Eli Casdin, Founder and Chief Investment Officer of Casdin Capital, will join DNA Script's Board of Directors.

Funding from this investment round will enable DNA Script to accelerate the development of its suite of enzymatic DNA synthesis (EDS) technologies — in particular, to support the commercial launch of the company's SYNTAX™ DNA benchtop printer.

DNA Script will soon begin testing the SYNTAX™ system with a select group of partners, with plans to launch a beta testing program later this year and take orders for the DNA printer by next year.

Over the long term, funding from the Series B financing will enable DNA Script to further develop the company's core enzymatic synthesis technology — in particular, towards the development of new synthesis platforms — as well as to ramp up its commercial and manufacturing capabilities.